Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine Model of Bladder Cancer.
BBN
PDH
PDK4
bladder cancer
mouse
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Mar 2023
08 Mar 2023
Historique:
received:
26
01
2023
revised:
28
02
2023
accepted:
02
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Pyruvate dehydrogenase kinase 4 (PDK4) is a mitochondrial isozyme in the PDK family (PDK1-4) partially responsible for phosphorylation of pyruvate dehydrogenase (PDH). Phosphorylation of PDH is thought to result in a pro-proliferative shift in metabolism that sustains growth of cancer cells. Previous data from our lab indicate the pan-PDK inhibitor dichloroacetate (DCA) or acute genetic knockdown of PDK4 blocks proliferation of bladder cancer (BCa) cells. The goal of this study was to determine the role of PDK4 in an in vivo BCa model, with the hypothesis that genetic depletion of PDK4 would impair formation of BCa. PDK4
Identifiants
pubmed: 36980540
pii: cancers15061654
doi: 10.3390/cancers15061654
pmc: PMC10046149
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA168524.
Pays : United States
Organisme : Leo and Anne Albert Charitable Trust
ID : NA
Références
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2120157119
pubmed: 35969774
J Med Chem. 2008 Jan 24;51(2):196-218
pubmed: 18020435
Oncotarget. 2014 Dec 30;5(24):12862-76
pubmed: 25404640
J Cancer. 2020 May 18;11(15):4397-4405
pubmed: 32489458
J Diabetes Investig. 2021 Jan;12(1):21-31
pubmed: 32628351
Toxicol Appl Pharmacol. 2016 Aug 1;304:42-7
pubmed: 27217333
Front Cell Dev Biol. 2022 Mar 09;10:849962
pubmed: 35356277
Front Immunol. 2019 May 07;10:944
pubmed: 31134063
Oncogene. 2017 Feb 16;36(7):989-998
pubmed: 27641336
J Med Chem. 2017 Feb 9;60(3):1142-1150
pubmed: 28085286
Mol Cell. 2021 Feb 18;81(4):691-707.e6
pubmed: 33382985
Oncoscience. 2018 Jun 29;5(5-6):172-173
pubmed: 30035181
Eur Urol. 2022 Oct;82(4):365-373
pubmed: 35643589
J Clin Invest. 2015 Jan;125(1):194-207
pubmed: 25437876
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Cancer Cell. 2007 Jan;11(1):37-51
pubmed: 17222789
Biochem Soc Trans. 2003 Dec;31(Pt 6):1168-70
pubmed: 14641019
Cancer Res. 2004 Jun 1;64(11):4040-8
pubmed: 15173019
Gan. 1973 Aug;64(4):331-6
pubmed: 4752369
Clin Cancer Res. 2019 Feb 1;25(3):977-988
pubmed: 29980530
Front Oncol. 2020 Dec 15;10:583217
pubmed: 33384955
Oncogene. 2018 Apr;37(14):1911-1925
pubmed: 29367767
Liver Res. 2018 Jun;2(2):100-107
pubmed: 31815032
Nat Rev Urol. 2020 May;17(5):259-270
pubmed: 32235944
Biochem J. 1984 Apr 15;219(2):635-46
pubmed: 6331393
Cancer Res. 1977 Feb;37(2):399-407
pubmed: 318920
Mol Cancer Ther. 2019 Oct;18(10):1673-1681
pubmed: 31511353
Oncogene. 2013 Oct;32(40):4814-24
pubmed: 23128392
J Cancer. 2019 Jan 29;10(4):918-926
pubmed: 30854098
Br J Cancer. 2013 Jan 15;108(1):72-81
pubmed: 23257894
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Oncoimmunology. 2020 Apr 16;9(1):1744897
pubmed: 32363111
Mol Cancer Ther. 2018 Sep;17(9):2004-2012
pubmed: 29907593
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Int J Gen Med. 2021 Dec 22;14:10141-10153
pubmed: 34992435
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618
pubmed: 28137924
Arch Physiol Biochem. 2006 Jul;112(3):139-49
pubmed: 17132539
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059435
Biochem Soc Trans. 2003 Dec;31(Pt 6):1143-51
pubmed: 14641014
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Eur Urol Oncol. 2019 Sep;2(5):497-504
pubmed: 31411998
Int J Mol Sci. 2022 Oct 31;23(21):
pubmed: 36362028
Neoplasia. 2022 Mar;25:18-27
pubmed: 35078134
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Mol Pharmacol. 2017 Mar;91(3):189-196
pubmed: 28003426
Clin Cancer Res. 2005 Jun 1;11(11):4029-36
pubmed: 15930337